UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

European heart journal, 2022-10, Vol.43 (39), p.3925-3946

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

The New England journal of medicine, 2019-03, Vol.380 (11), p.1022-1032

2019

Link zum Volltext

Verfügbarkeit prüfen

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

The New England journal of medicine, 2020-04, Vol.382 (16), p.1520-1530

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options

The Lancet (British edition), 2019-08, Vol.394 (10199), p.697-708

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Diabetes care, 2017-01, Vol.40 (1), p.69-76

2017

Link zum Volltext

Verfügbarkeit prüfen

Epidemiology of familial hypercholesterolaemia: Community and clinical

Atherosclerosis, 2018-10, Vol.277, p.289-297

2018

Link zum Volltext

Verfügbarkeit prüfen

Mendelian Randomization Study of ACLY and Cardiovascular Disease

The New England journal of medicine, 2019-03, Vol.380 (11), p.1033-1042

2019

Link zum Volltext

Verfügbarkeit prüfen

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

Circulation (New York, N.Y.), 2018-08, Vol.138 (8), p.770-781

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

The Lancet (British edition), 2009-05, Vol.373 (9677), p.1765-1772

2009

Link zum Volltext

Verfügbarkeit prüfen

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1

Cardiovascular research, 2021-01, Vol.117 (1), p.284-291

2021

Link zum Volltext

Verfügbarkeit prüfen

PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?

Heart (British Cardiac Society), 2017-11, Vol.103 (21), p.1670

2017

Link zum Volltext

Verfügbarkeit prüfen

Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis

Atherosclerosis, 2018-08, Vol.275, p.434-443

2018

Link zum Volltext

Verfügbarkeit prüfen

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Diabetes care, 2019-01, Vol.42 (1), p.173-176

2019

Link zum Volltext

Verfügbarkeit prüfen

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population

Circulation (New York, N.Y.), 2016-11, Vol.134 (19), p.1419-1429

2016

Link zum Volltext

Verfügbarkeit prüfen

Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries

Frontiers in cardiovascular medicine, 2019-01, Vol.5, p.199-199

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms

Atherosclerosis, 2016-10, Vol.253, p.194-208

2016

Link zum Volltext

Verfügbarkeit prüfen

Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials

Atherosclerosis, 2015-08, Vol.241 (2), p.433-442

2015

Link zum Volltext

Verfügbarkeit prüfen

Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies

BMC medicine, 2015-09, Vol.13 (1), p.229-229, Article 229

2015

Link zum Volltext

Verfügbarkeit prüfen

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials

Atherosclerosis, 2019-09, Vol.288, p.194-202

2019

Link zum Volltext

Verfügbarkeit prüfen

Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis

Annals of medicine (Helsinki), 2022-12, Vol.54 (1), p.1287-1296

2022

Link zum Volltext

Verfügbarkeit prüfen

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

The lancet. Diabetes & endocrinology, 2016-10, Vol.4 (10), p.850-861

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

Journal of the American College of Cardiology, 2008-02, Vol.51 (7), p.724-730

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 464

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(424)
Mit Volltextzugriff
(412)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(330)
Life Sciences & Biomedicine
(319)
Humans
(254)
Cardiovascular System & Cardiology
(199)
Cardiac & Cardiovascular Systems
(181)
Risk Factors
(105)
Female
(100)
Cardiovascular Disease
(99)
Male
(97)
Cholesterol
(84)
Middle Aged
(80)
Statins
(79)
Hydroxymethylglutaryl-Coa Reductase Inhibitors - Therapeutic Use
(75)
Treatment Outcome
(69)
Peripheral Vascular Disease
(68)
Diabetes
(61)
Cardiovascular Diseases - Prevention & Control
(55)
Aged
(54)
Lipids
(53)
Cardiovascular Diseases
(52)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Epidemiology of familial hypercholesterolaemia: Community and clinical

Mendelian Randomization Study of ACLY and Cardiovascular Disease

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1

PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population

Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries

Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms

Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials

Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials

Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

Suchergebnisse filtern